VJOncology Podcast

Highlights in GI cancer from ESMO WCGIC 2023

The ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 brought together world-renowned experts in oncology to present and discuss the latest advances in gastrointestinal cancer. In this podcast, we hear from leading healthcare professionals as they provide an overview of highlights from this year’s meeting. We will be joined by Philip Philip (Wayne State University School of Medicine/Henry Ford Health, Detroit, MI), Shouki Bazarbashi (King Faisal Specialist Hospital and Research Center-Riyadh, Riyadh, Saudi Arabia), and Anna Wagner (University of Lausanne, Lausanne, Switzerland).

 

We will hear on the feasibility of precision medicine approaches in pancreatic cancer, as well as findings from the INNOVATION trial, which assessed chemotherapy with trastuzumab and pertuzumab in patients HER2-positive gastric cancer. Several colorectal trials will additionally be discussed, including VELO, DEEPER, IMPROVE and AVETRIC, which all assessed the feasibility of panitumumab or cetuximab in the metastatic setting.

Updates in immunotherapy for head and neck cancer

In this podcast we’ll be covering some of the latest updates in immunotherapy for head and neck cancer. Ezra Cohen, MD, FRCPSC, FASCO, Moores Cancer Center at UC San Diego Health, San Diego, CA, discusses the clinical activity of petosemtamab, a bispecific antibody targeting EGFR and LGR5, in patients with head and neck squamous carcinoma (HNSCC). Nabil Saba, MD, FACP, Winship Cancer Institute of Emory University, Atlanta, GA, presents findings from a Phase II trial (NCT03468218) of pembrolizumab and cabozantinib in patients HNSCC. Ari Rosenberg, MD, Yale School of Medicine, New Haven, CT, describes the trial design of the Phase II DEPEND trial (NCT03944915), which assessed neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation (CRT) in locoregionally advanced HPV-negative HNSCC. Blessie Elizabeth Nelson, MBBS, DMRT, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the ongoing study investigating the synergy between the potential efficacy of Clostridium novyi with pembrolizumab. Lastly, Heath Devin Skinner, MD, PhD, Hillman Cancer Center, Pittsburgh, PA, shares findings from the Phase II study (NCT03715946), which aimed to investigate treatment de-intensification for resected human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) by adding nivolumab to a reduced radiation therapy (RT) regimen.

iwCAR-T session VI: Advances in GI cancers

The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April 2023, and brought together world-leading experts in CAR-T therapy as they discussed the latest in the field. In this podcast series, you will gain an insight into the sessions that took place at this year’s meeting, which covered the latest updates in CAR-T therapy in solid tumors, as well as associated challenges.

 

In this engaging discussion, we are excited to be joined by three distinguished experts in the field of oncology, J. Randolph Hecht, MD, from UCLA Santa Monica Medical Center, Santa Monica, CA, who will chair this discussion, Diane Simeone, MD, from NYU Langone Health, New York City, NY, and Xianxin Hua, MD, PhD, from the University of Pennsylvania, Philadelphia, PA. Listen to uncover the cutting-edge techniques and novel strategies employed in CAR-T therapy, all intended to revolutionize the treatment landscape of GI cancers.

Highlights in bladder cancer at ASCO 2023: NORSE, RAGNAR, and THOR

In this episode, we will be covering highly anticipated updated in urothelial carcinoma presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023 in Chicago, IL. We are joined by Arlene Siefker-Radtke, MD of The University of Texas MD Anderson Cancer Center. Professor Siefker-Radtke is a leading expert in genitourinary cancer and will be sharing insights and updates from the ASCO 2023 Annual Congress, including a discussion of the NORSE (NCT03473743), THOR (NCT03390504), and RAGNAR (NCT04083976) trials. These trials investigated the use of the FGFR inhibitor, erdafitinib, in comparison or combination with other therapies.

ASCO 2023 Highlights: THOR, INDIGO and ADAURA

The American Society of Clinical Oncology Annual Meeting 2023 brought together thousands of experts in oncology to hear new data and discuss how to improve the diagnosis and treatment of patients with cancer. In this podcast, we hear from leading experts as they discuss some of the most groundbreaking trials from this year’s meeting. We will be joined by Yohann Loriot (Gustave Roussy, Villejuif, France), Karan Dixit (Northwestern Memorial Hospital, Chicago, IL), Roy S. Herbst (Yale School of Medicine, New Haven, CT), Ticiana Leal (Winship Cancer Institute of Emory University, Atlanta, GA), Jason Luke (University of Pittsburgh, Pittsburgh, PA).

We will hear on the THOR study evaluating erdafitinib in metastatic urothelial cancer with FGFR alterations and the INDIGO trial of vorasidenib in residual or recurrent grade 2 glioma with an IDH1/2 mutation. There will also be discussion on the ADAURA trial investigating adjuvant osimertinib in resected EGFR‑mutated stage IB–IIIA non-small cell lung cancer, the LUNAR trial evaluating Tumor Treating Field therapy with standard of care in metastatic non-small cell lung cancer following platinum failure. The KEYNOTE-716 study, which assessed pembrolizumab in patients with high risk stage IIB or IIC cutaneous melanoma will also be discussed.

iwCAR-T Session III: CAR-T clinical advances in lung cancer

The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April 2023, and brought together world-leading experts in CAR-T therapy as they discussed the latest in the field. In this podcast series, you will gain an insight into the sessions that took place at this year’s meeting, which covered the latest updates in CAR-T therapy in solid tumors, as well as associated challenges.

In this engaging discussion, we are honored to be joined by three distinguished experts in the field of oncology, Prasad Adusumilli, MD, FACS, from Memorial Sloan Kettering Cancer Center, New York, NY, Adam Schoenfeld, MD, also from Memorial Sloan Kettering Cancer Center, New York, NY, and William Go, MD, PhD, from A2 Biotherapeutics in Agoura Hills, California. Listen to gain a deep understanding of the cutting-edge approaches and novel strategies employed in CAR-T therapy, all aimed at revolutionizing the treatment landscape for lung cancer. 

iwCAR-T Session II: Cell therapies in GU cancers

The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April 2023, and brought together world-leading experts in CAR-T therapy as they discussed the latest in the field. In this podcast series, you will gain an insight into the sessions that took place at this year’s meeting, which covered the latest updates in CAR-T therapy in solid tumors, as well as associated challenges.

Join Vivek Narayan, Saul Priceman, and Nicholas Zorko in this compelling podcast episode recorded during the iwCAR-T meeting. Focusing on genitourinary malignancies, particularly prostate and urothelial cancer, the experts discuss the promises and hurdles of NK cell therapies, unresolved questions surrounding NK cell infiltration and manufacturing as well as obstacles in engineering T cells for the immunologically cold environment of prostate cancer. Insights into the role of lymphodepletion chemotherapy and the advantages of targeting B7-h3 as an antigen in prostate cancer are also explored. 

iwCAR-T Session I: Emerging CARs and future challenges in solid tumors

 

Experts Julian Molina (Mayo Clinic, Rochester, MN), Mathew Angelos (University of Pennsylvania, Philadelphia, PA), and Sebastian Kobold (Ludwig-Maximilians-University of Munich, Munich, Germany) bring you updates live from the International Workshop of CAR-T and Immunotherapies (iwCART) 2023.

In considering the latest research and trials in the field of CAR T-cell therapy and the challenges associated with treating solid tumors, these specialists discuss using CAR macrophages in combination with other immunotherapies, manipulating the tumor microenvironment, the genetic engineering of CAR T-cells to add and/or remove specific factors and tumor heterogeneity.

Highlights at AACR 2023: mRNA vaccines in melanoma and novel RAF inhibitors

In this podcast, we’ll be covering highlights from the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL, including personalized mRNA and neoantigen vaccines, nivolumab with the standard of care in prostate cancer, and BGB-3245, a novel RAF dimer inhibitor, in solid tumors. Hear from Jeffrey Weber, NYU Langone Perlmutter Cancer Center, NY, Mansi Saxena, Icahn School of Medicine at Mount Sinai, New York, NY, John Michael Bryant, Moffitt Cancer Center, Tampa, FL, and Alison Schram, Memorial Sloan Kettering Cancer Center, New York, NY, who will all talk on these exciting advances.

Liquid biopsy in lung cancer: precision medicine and MRD

In this podcast, we’ll be discussing the use of liquid biopsy in lung cancer, with Professor Klaus Pantel of University Medical Center Hamburg-Eppendorf, in Hamburg, Germany. At the European Lung Cancer Congress (ELCC) 2023, we spoke with Professor Pantel about possible areas where liquid biopsy could be useful, such as clinical trial recruitment, as well as practical considerations for the use of liquid biopsies, and the role of MRD status in the management of non-small cell lung cancer.